Developing a single method for the quantification of related compounds for a combination product containing three active ingredients is difficult task. Separation and compromising run time to elute all known and unknown degradation products are crucial for a combination product. The aim of current work is to develop a new stability indicative method and validate for a fixed dose combination product containing dolutegravir, lamivudine, tenofovir disoproxil fumarate and their potential impurities in a single run by HPLC. The critical separation between dolutegravir, lamivudine, tenofovir disoproxil fumarate and its impurities was successfully attained by a new core-shell bi-phenyl, 250x4.6mm, 5µm column with a run time of 150 min. The run time was 150min. Forced degradation studies were verified to prove the stability-indicating nature of the method. Stability-indicating nature was confirmed by peak purity of all the three active components and impurities. The developed method was validated to prove the potentiality of the method as per ICH guidelines with respect to specificity, linearity, accuracy, precision ad robustness. The sensitivity of the method was proved by establishing limit of detection (LOD) and limit of quantification (LOQ) of for dolutegravir, lamivudine, tenofovir disoproxil fumarate and potential impurities.
A new UPLC method was developed for identification and quantification of process related impurities and degradation products in a new fixed dose combination product of empagliflozin and linagliptin tablets, which is used to treat type-2 diabetes. Chromatographic separation was obtained using a new phenomenex Luna omega polar C18, 100x2.1mm, 1.6µ and a gradient programme consisting of Mobile phase A: 10mM Potassium dihydrogen orthophosphate pH-3.0 and Mobile phase B: acetonitrile and methanol (55:45%v/v). Degradation impurities were monitored at a common wavelength of 225nm. The run time was 40 minutes within this run time the five related compounds, all major degradation impurities of empagliflozin and linagliptin were eluted which reduces the analysis time and solvent consumption. The combined drugs as well as individual blends were subjected to hydrolysis (water, acid and base), oxidative, photolytic and thermal stress conditions. Mass of major unknown degradation products were determined by LC-PDA coupled with a new QDA mass detector. The protanated molecular ion peaks for linagliptin at M+H were DP1-514.19 in water, acid, base, oxidative, photolytic and thermal stress conditions. DP2-515.14 in acid and base hydrolysis. DP3-544.18 in acid hydrolysis. For empagliflozin DP4-365.13 in base hydrolysis. DP5-487.16 and DP6-487.14 in peroxide hydrolysis. DP7-470.91, DP8-502.08, DP9-538.01, DP10-326.98 and DP11-293.02 in acid hydrolysis. The developed method was validated as per international conference on harmonization guidelines (ICH) with respect to specificity, linearity, limit of detection (LOD), limit of quantification (LOQ), accuracy, precision and robustness.
The objective of this current work was to develop and validate a rapid, sensitive, rugged, simple, single method for the determination and quantification of degradation products as well as process impurities by HPLC coupled with PDA, QDA mass detector and same method was also scalable to UPLC for a fixed dose combination containing dolutegravir, emtricitabine and tenofovir disoproxil fumarate. Chromatographic separation was achieved using a new Core-Shell Bi-phenyl column for both HPLC and UPLC and a gradient programme consisting of Mobile phase A: Ammonium acetate (pH 3.0 buffer) and Mobile phase B: Ammonium Acetate (pH 3.0 buffer) with Methanol and Acetonitrile. The run time was 120 minutes for HPLC and 45 minutes for UPLC within which dolutegravir, emtricitabine, tenofovir disoproxil fumarate and its fourteen related compounds were eluted. Drug was subjected to hydrolysis (acid and base), oxidative, photolytic and thermal stress conditions. The unknown degradation products were identified by PDA/QDA mass detector. Which revealed protonated molecular ion peaks [M=H at m/z DP1-418.21 and DP2-418.18 for sample preparation in acid and base hydrolysis, at m/z DP3-416.04, DP4-663.17, DP5-490.14, DP6-819.21 and DP7-606.14 for thermal degradation sample and at m/z for Dolutegravir API in acid hydrolysis condition. A cogent mechanism for the formation of degradation and process impurities was proposed. The performance of the developed method was validated as per International Conference on Harmonization guidelines (ICH) with respect to specificity, linearity, limit of detection (LOD), limit of quantification (LOQ), accuracy, precision and robustness.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.